Text Size

The Role of Tea Catechins and Caffeine in Relation to Energy Metabolism

This study has been completed.
Sponsor:
Collaborator:
Unilever R&D
Information provided by:
University of Copenhagen
ClinicalTrials.gov Identifier:
NCT00611416
First received: August 21, 2007
Last updated: February 6, 2009
Last verified: February 2009
History of Changes
  Purpose

The aim of this study is to elucidate the role of specific catechins, a mixture of catechins and caffeine in relation to weight control with particular emphasis on energy metabolism and fat oxidation.


Condition Intervention
Obesity
 Dietary Supplement: green tea
Dietary Supplement: Mix of catechins and caffeine
Dietary Supplement: EGCG
Dietary Supplement: EGC
Dietary Supplement: Caffeine
Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Role of Tea Catechins and Caffeine in Relation to Energy Metabolism in Man

Resource links provided by NLM:

MedlinePlus related topics: Caffeine Obesity
U.S. FDA Resources

Further study details as provided by University of Copenhagen:

Primary Outcome Measures:
  • fat oxidation [ Time Frame: november 2007 ]

Secondary Outcome Measures:
  • appetite [ Time Frame: november 2007 ]

Enrollment: 15
Study Start Date: November 2005
Study Completion Date: February 2006
Arms Assigned Interventions
Experimental: 1
Active treatment A
 Dietary Supplement: green tea
different catechin combinations
Dietary Supplement: Mix of catechins and caffeine
3 tablet a day
Experimental: 2
Active treatment B
 Dietary Supplement: green tea
different catechin combinations
Dietary Supplement: EGCG
3 tablets a day
Other Name: epigallocatechin gallate
Experimental: 3
Active treatment C
 Dietary Supplement: green tea
different catechin combinations
Dietary Supplement: EGC
3 tablets a day
Other Name: Epigallocatechin
Active Comparator: 4
Positive control
 Dietary Supplement: Caffeine
3 tablets a day
Placebo Comparator: 5
Placebo
 Dietary Supplement: Placebo
3 tablets a day

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy men
  • Age 18-40 years
  • BMI 18,5-25 kg/m2

Exclusion Criteria:

  • Diabetes or any other endocrinological disease
  • Hypertensive medication
  • Increased Blood Pressure > 140/85
  • Hyperlpidimia
  • Chronic disease (i.e. HIV)
  • Use of any diet supplements including vitamins (during and 3 months prior to the study).
  • High alcohol intake (>21 units a week)
  • High caffeine intake (>250 mg/day) or high catechin intake (>200 mg/day)
  • Smoking
  • Elite sports performer
  • Use of any regular medication
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00611416

Locations
Denmark
Institute of Human Nutrition, The Royal Veterinary and Agricultrual University
Frederiksberg C, Denmark, 1958
Sponsors and Collaborators
University of Copenhagen
Unilever R&D
Investigators
Study Chair: Arne Astrup, Proffessor Insitute of Human Nutrition
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00611416     History of Changes
Other Study ID Numbers: (KF) 01 279421, Unilever
Study First Received: August 21, 2007
Last Updated: February 6, 2009
Health Authority: Denmark: The Danish National Committee on Biomedical Research Ethics

Keywords provided by University of Copenhagen:
catechins
caffeine
energy expenditure
fat oxidation
appetite

Additional relevant MeSH terms:
Obesity
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Caffeine
Epigallocatechin gallate
Central Nervous System Stimulants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
 Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Antioxidants
Protective Agents
Antimutagenic Agents
Anticarcinogenic Agents
Antineoplastic Agents
Neuroprotective Agents

ClinicalTrials.gov processed this record on May 23, 2013